menu
    • menu
    [{"orgOrder":0,"company":"Nordic Capital","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nordic Capital","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.84999999999999998,"dosageForm":"Powder for Concentrate for Solution for Infusion\n","sponsorNew":"Nordic Capital \/ Nordic Capital","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Capital \/ Nordic Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Capital

    Menu

    Nordic Capital

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nordic Capital

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Nordic Capital

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftobiprole Medocaril

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Advanz Pharma

                            Deal Size : $846.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Nordic Capital Acquires Advanz Pharma for $846 Million

                            Details : Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.

                            Brand Name : Zevtera

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 01, 2021

                            Lead Product(s) : Ceftobiprole Medocaril

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Advanz Pharma

                            Deal Size : $846.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth